PHKA2

Across TCGA pan-cancer cohorts, PHKA2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PHKA2 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PHKA2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PHKA2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where PHKA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.202	0.988	.002	23	view →
LUAD	DFS	Quartile	III,IV	0.298	0.995	.004	10	view →
LSCC	DFS	Median	II,III,IV	0.805	0.555	.014	6	view →
UCEC	DFS	Median	All	0.936	1.000	.023	2	view →
HNSC	OS	Median	IV	0.826	0.641	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PHKA2–PDAC (OS)

Open the PDAC breakdown →